Corporate Overview

We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases.

Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immunity responses. EB05 (paridiprubart) inhibits Toll-like receptor 4 (TLR4), a key immune signaling protein and an important mediator of inflammation. We are currently evaluating EB05 as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life threatening form of respiratory failure. Based in part on the Phase 2 results  of our Phase 2/3 study, the U.S. FDA granted us Fast Track designation. To receive this designation, drug candidates must both treat a serious disease and have non-clinical or clinical data that demonstrate the potential to address an unmet medical need.

We are also developing product candidates for a number of chronic dermatological and inflammatory conditions. We recently reported topline results of a Phase 2b study of our EB01 (daniluromer) drug candidate in moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common, often work-related skin condition. We have an approved clinical trial application for our EB06 monoclonal antibody candidate to conduct a future Phase 2 study in vitiligo. We are also preparing an IND for our EB07 product candidate (paridiprubart) to conduct a future Phase 2 study in systemic sclerosis (SSc).

Edesa is a clinical-stage biopharma company focused on inflammatory and autoimmune diseases

Financial Reports

Investors News

News Alerts

Investors Relations

Edesa Biotech, Inc.
Attn: Investor Relations
100 Spy Court
Markham, ON L3R 5H Canada

(289) 800.9600



Legal Counsel

Fasken Martineau DuMoulin LLP


Transfer Agent

Computershare Investor Services Inc.
100 University Avenue, 8th Floor
Toronto, Ontario M5J 2Y1

Tel: (800) 564-6253